Certara
CompanyUnited StatesFounded 2007
Certara develops one asset, in phase 3 (Sonlicromanol in m.3243A>G-related primary mitochondrial disease). Mostly small molecule acting on Oxidative stress and ROS signalling, oxidative phosphorylation and inflammation; based in the United States, founded in 2007.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 0
- Signals
Pipeline
1Modulates reductive and oxidative distress with anti-inflammatory properties; its active metabolite inhibits microsomal prostaglandin E synthase-1.
Phase 3, Small molecule, Oxidative stress and ROS signalling, Oxidative phosphorylation, m.3243A>G-related primary mitochondrial disease, maternally inherited diabetes and deafness, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms6
- Trials1
- Signals1
- Integrity notices2
- Similar companies6